Jing

Press ReleaseChengdu, China, April 10, 2024Anticancer Bioscience unveils groundbreaking MYC-Synthetic Lethal Therapy at AACR 2024 Chengdu, China, April 10, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that their research team at the 2024 AACR Conference introduced a pioneering therapy aimed at cancer with the deregulated …

Anticancer Bioscience unveils groundbreaking MYC-Synthetic Lethal Therapy at AACR 2024 Read More »

Press ReleaseChengdu, China, September 22, 2022Anticancer Bioscience named a finalist for China Biopharma Leadership Award by Scrip Chengdu, China, September 22, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that it has been named as a finalist for the 2022 Scrip Awards in the category of China …

Anticancer Bioscience named a finalist for China Biopharma Leadership Award by Scrip Read More »

Press ReleaseChengdu, China, May 18, 2022Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology Chengdu, China, May 18, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, based in China, and DelSiTech Ltd, the leading silica drug delivery technology company, based in …

Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology Read More »

Press ReleaseChengdu, China, April 19, 2022Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader Chengdu, China, April 19, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that its Founder, President and CEO, Dun Yang, PhD has been named as …

Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader Read More »

Press ReleaseChengdu, China, January 17, 2022Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics Chengdu, China, January 17, 2022 - The Discovery Oncology (DO) group and the Natural Product Drug Discovery (NPDD) group of Anticancer Bioscience (ACB) collaboratively published another interesting study that uncovers a novel mechanism by which a natural …

Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics Read More »